Digest Réseau Comment ça marche
Réseau
/
Sociétés
No
Non vérifié

Novo Nordisk A/S

Ce que nous écrivons

FinanceIndustrie pharmaceutiqueManagement/Organisation d'EntreprisePolitique ÉtrangèrePublicité/Marketing/Médias/Communication

91 communiqués de presse

Voir tous les communiqués de presse
05/05/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Politique Étrangère
Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
28/04/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Publicité/Marketing/Médias/Communication
Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
23/04/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
20/04/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
13/04/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
09/04/2026
Industrie pharmaceutique
Publicité/Marketing/Médias/Communication
Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
26/03/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
26/03/2026
Industrie pharmaceutique
Politique Étrangère
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
24/03/2026
Industrie pharmaceutique
Management/Organisation d'Entreprise
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0
19/03/2026
Industrie pharmaceutique
Politique Étrangère
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Source
Novo Nordisk A/S
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0